Dive Brief:
- An experimental CG Oncology drug significantly reduced the risk of bladder cancer recurrence in a Phase 3 trial, positioning the company to seek clearance of its therapy as an early intervention in certain people with the disease.
- CG’s therapy cretostimogene was evaluated against standard surveillance following surgery in people with intermediate-risk and high-grade non-muscle invasive bladder cancer. After 17 months of follow-up, the treatment cut the relative risk of relapse by 68% compared to the control arm, meeting its main objective, the company said Monday.
- Safety results were consistent with what’s been reported in previous testing. Investigators didn’t observe any drug-related adverse events that were “severe” or worse, and no recipients stopped treatment due to side effects. More specific details will be presented at a medical meeting next month. Company shares climbed 12%, pushing CG’s market value close to $8 billion.
Dive Insight:
CG aims to upend care in non-muscle invasive bladder cancer, where cancer cells haven’t yet spread beyond the bladder’s inner lining.
These tumors are usually treated with an immunotherapy called BCG following a tumor resection. But those interventions aren’t always effective and many patients who respond see their disease return afterward, leading to more drastic options like surgical removal of the bladder.
CG has touted its drug cretostimogene as a potential “backbone” therapy that could be useful in multiple treatment settings. It’s a type of immunotherapy known as an oncolytic virus, which infects and kills cancer cells while alerting the immune system.
The drug’s potential led CG to pull off a $380 million initial public offering in 2024 and subsequently more than double its market value. And since then, the drug has succeeded in two Phase 3 trials in two different settings. CG is already working on an approval request in people who haven’t responded to BCG therapy, for instance. Though it’s pushed back the timelines for that submission multiple times, the company now expects to complete the filing early next year.
The latest results will support another application next year in a setting that doesn’t have a therapeutic option. It also positions cretostimogene as “likely the only agent” to become available in both settings in non-muscle invasive bladder cancer, wrote TD Cowen analyst Tyler Van Buren. The risk reduction the company recorded is “exceptional” and tops the 30% to 40% range management and investors had been hoping the treatment would surpass, he wrote.
“Today’s data clears even the most optimistic bars,” added RBC Capital Markets analyst Leonid Timashev, though he cautioned that the full dataset CG presents next month will be critical to “better understand” exactly how the drug performed.
Timashev estimates that cretostimogene could generate up to $3.2 billion in peak annual U.S. sales by 2035.